Sino Biopharmaceutical inks a licensing deal with AstraZeneca for a respiratory drug, with milestones and royalties worth ...

Miami (March 4, 2026) – Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors ...

Like high blood pressure, fatty liver disease has a way of sneaking up on people, often not causing noticeable symptoms until you receive a diagnosis. And when that diagnosis comes, you may not be ...

By Andrew Silver July 8 (Reuters) - AstraZeneca will pay a subsidiary of Sino Biopharmaceutical $200 million upfront for the ...

FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...

Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...

Inhalers and nebulizers are necessary when managing chronic obstructive pulmonary disease (COPD). Both are designed to deliver medication directly to the lungs, which helps in reducing symptoms, ...

Cognitive function, hand dexterity, and breathing ability play an important role in helping people with chronic obstructive ...

July 8 (Reuters) - Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China unit had secured rights to ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes. Objectives: Despite ...

SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 receptor ...